p38 inhibiteur de Kinase sur carte IV, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

p38 MAP Kinase Inhibitor IV has been used for blocking p38α kinase activation in order to examine if HOXB7 is involved in the regulation of migration and proliferation process via AKT/MAPK signaling.

Biochem/physiol Actions

p38 MAP Kinase Inhibitor IV is an ATP-competitive inhibitor of p38α/β MAPK with IC₅₀ values of 130 nM for p38α and 550 nM for p38β. It is much less active with ≤23% inhibition at 1 µM against p38γ/σ, ERK1/2, and JNK1/2/3. Shown to be more effective than SB 203580 in inhibiting LPS-induced IL-1β release from hPBMC (100% vs. 50% inhibition with 100 µM inhibitor). A recent study showed that p38 MAP Kinase Inhibitor IV could consistently and significantly enhance reprogramming and iPS cell generation from somatic cells.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle